| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(6 years from now) | |
Recarbrio is owned by Msd Merck Co.
Recarbrio contains Cilastatin Sodium; Imipenem; Relebactam.
Recarbrio has a total of 1 drug patent out of which 0 drug patents have expired.
Recarbrio was authorised for market use on 16 July, 2019.
Recarbrio is available in powder;intravenous dosage forms.
Recarbrio can be used as treatment of complicated intra-abdominal infections (ciai); treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); treatment of complicated urinary tract infections, including pyelonephritis (cuti).
Drug patent challenges can be filed against Recarbrio from 2028-07-16.
The generics of Recarbrio are possible to be released after 19 November, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 2028-07-16
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...
Dosage: POWDER;INTRAVENOUS
RECARBRIO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic